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Fourteen patients with atrial fibrillation or flutter and
a ventricular rate of 2: 120 beats/min occurring after
cardiac surgery entered a double-blind placebo-con-
trolled conditional crossover trial of intravenous pro-
pafenone. Patients randomly received either propafen-
one (2 mg/kg body weight) or placebo during a 10 minute
intravenous infusion. If 20 minutes after the initiation
of this infusion there was no conversion to sinus rhythm,
the patient received a second intravenous infusion over
10 minutes (either propafenone or placebo, whichever
was not given first). The electrocardiogram was recorded
continuously throughout the study.
Fourteen patients received propafenone and 10 re-
ceived placebo. No patient's rhythm converted to sinus
Propafenone is an investigational antiarrhythmic agent that
is useful for the control of both atrial and ventricular ar-
rhythmias including ventricular tachycardia (I), ventricular
premature beats (2) and atrioventricular (AV) node recip-
rocating tachycardia (3). Although there is fragmentary evi-
dence indicating that propafenone may be useful in atrial
fibrillation (4,5), there have been no placebo-controlled trials
of propafenone for this arrhythmia. Propafenone prolongs
atrial refractoriness and slows intraatrial and AV node con-
duction (I). These properties should be beneficial for treat-
ment of atrial fibrillation or flutter. both for promoting con-
version to sinus rhythm and for slowing the ventricular
response.
Atrial fibrillation and flutter occur frequently after open
heart surgery (6,7). These arrhythmias are usually of short
duration and revert spontaneously, but in some patients
hemodynamic compromise may necessitate prompt inter-
vention. Although digoxin (8), verapamil (9) and beta-ad-
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rhythm after placebo. In six patients (43%) (p < 0.001),
the arrhythmia converted to sinus rhythm between 5 and
10 minutes after the end of the propafenone infusion.
After propafenone, the ventricular response to atrial
fibrillation or flutter decreased significantly from 141.6
± 15.2 to 116.0 ± 15.5 beats/min. Ventricular rate did
not change after placebo. The mean propafenone plasma
concentration was 3.46 ± 2.17 mg/liter. The only side
effect of propafenone noted was a decrease in systolic
blood pressure of 9 ± 9 mm Hg. Propafenone was useful
for management of atrial fibrillation after cardiac sur-
gery both for control of rapid ventricular response and
for conversion to sinus rhythm.
(J Am Coli Cardiol /987;10:1145-8)
renergic blockers (10) can slow ventricular rate, they rarely
convert the arrhythmia to sinus rhythm. Sodium channel
blocking drugs such as disopyramide (7) and procainamide
( II) convert some patients' arrhythmias to sinus rhythm;
however. they do not decrease the ventricular response in
atrial fi brillation.
In this report. we present the results of a double-blind
placebo-controlled conditional crossover trial of propafen-
one for control of ventricular rate and for conversion of
atrial fibrillation or flutter complicating open heart surgery.
Methods
Study patients. Patients who had had open heart surgery
within 3 weeks and who developed atrial fibrillation or atrial
flutter with a mean ventricular response of 2: 120 beats/min
were eligible for inclusion in this study. In one patient who
qualified for the study. the ventricular response to atrial
fibrillation decreased to 116 beats/min in the minute pre-
ceding drug administration. This patient was included in the
analysis.
Patients were excluded from the study [or the following
reasons: I) age <21 years or >75 years; 2) history of
myocardial infarction within I month: 3) receipt of beta-
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blocker or calcium antagonist or other antiarrhythmic drugs
(except digoxin); 4) systolic blood pressure < 90 mm Hg:
5) congestive heart failure; 6) severe obstructive pulmonary
disease; and 7) unwillingness or inability to give written
informed consent, or extubation not yet performed.
Basel ine data obtained at the initiation of the protocol
included history and physical examination. blood chemistry
values, hematologic profile, urinalysis and electrocardio-
gram (ECG) with a rhythm strip and at least 5 minutes of
continuous ECG recording.
Study design. A double-blind randomized placebo-con-
trolledconditionalcrossoverdesign was used. Initially, each
patientreceived drug A (propafenone [2 mg/kg body weightI
or placebo) intravenously over 10 minutes. If the patient' s
arrhythmia did not revert to sinus rhythm within 20 minutes
of the start of the infusion of drug A, then drug B (placebo
or propafenone [2 mg/kg], whichever was not given as drug
A), was administered intravenously over 10 minutes. Pa-
tients whose arrhythmia was converted to sinus rhythm within
20 minutes of the start of drug A did not receive drug B.
The ECG (lead MCLd was recorded continuously from 5
minutes before the start of the infusion of drug A until 10
minutesafter the end of the infusion of drug B. A continuous
ECG rhythm strip was saved for later analysis of heart rate.
Blood pressure was measured by sphygmomanometer at I
minute intervals during drug infusions, at 10 minute inter-
vals for 90 minutes and then every 4 hours for 24 hours.
Conversion to sinus rhythm was attributed to the drug if
it occurred during drug infusion or within 10 minutes of the
end of the infusion. Ten minutes after the end of the second
drug infusion, the study ended and treatmentby the referring
physicians was resumed. Ventricular response to atrial fi-
brillation or flutter was determined by counting the QRS
complexes in 1 minute of the continuous rhythm strip. Ve-
nous blood samples were obtained within 5 minutes of the
Table l. Clinical Characteristics of 14 Male Patients
end of each drug infusion. Plasma was then extracted and
frozen for later analysis of propafenone plasma concentra-
tion by a gas chromatographic method.
Data analysis. A Fisher's exact test was used to compare
the rates of conversion to sinus rhythmbetween propafenone
and placebo. Paired Student's t tests were used to evaluate
the effects of propafenone and placebo on the ventricular
response in atrial fibrillation and on blood pressure. An
unpaired Student's t test was used to compare propafenone
plasma concentrations in responders and nonresponders. This
protocol was approved by the Ethics Committee of our hos-
pital.
Results
Clinical features. Fourteen patients were studied be-
tween 2 and 17 days after cardiac surgery (Table I). All
patients were alert and extubated at the time of study. They
were all men ranging in age from 25 to 72 years. The mean
duration of atrial fibrillation or flutter before drug admin-
istration was 8.4 hours (range I to 28). Six patients had
received intravenous digoxin (0.25 to 1.0 mg during the 24
hours before study). In all cases. at least 4 hours had elapsed
between the administration of any digoxin and the admin-
istration of study drugs.
Incidence of conversion to sinus rhythm. All 14 pa-
tients received propafenone, 6 as drug A and 8 as drug B.
Only 10 patients received placebo because 4 patients who
received propafenoneas drug A (that is. first) hadconversion
to sinus rhythmand, therefore, did not receive drug B. Table
2 shows the rates of conversion to sinus rhythm for pro-
pafenone and placebo. No conversion to sinus rhythm oc-
curred after administrationof placebo. In six patients (43%)
conversion to sinus rhythm occurred between 5 and 10 min-
utes after receipt of propafenone (p < 0.00 1).
Patient Age Type of Days Duration of Received
No. (yr) Surgery Postop Arrhythmia Arrhythmia (h) Digoxin
I 62 CABG 3 AF 1.5 No
2 72 CABG/AVR 2 AF 6 Yes
.3 56 CABG 2 AF 3.5 No
4 57 CABG 3 AF 28 No
5 53 CABG 3 AF 8 Yes
6 66 CABG 5 AF 10 Yes
7 62 CABG 2 AF 7 Yes
II 60 CABG 5 AF 12 Yes
9 67 CABG 17 AFL 5 No
10 57 CABG 2 AF 4 No
I I 70 AVR 2 AF I No
12 59 CABG 2 AF 6 Yes
13 47 AVR 2 AF 1 No
14 25 ASD 15 AFL 24 No
Hours Since Last
Dose of Digoxin
5
10
13
6
4
5.5
AF = atrial fibrillation; AFL = atrial flutter: ASD = repair of atrial septal defect; AVR = aortic valve replacement; CABG = coronary artery
bypass graft surgery; Postop = postoperative.
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Table 2. Rate of Conversion to Sinus Rhythm in 14
Male Patients
concentration in the patients who did and did not have con-
version to sinus rhythm.
Discussion
Atrial fibrillation and flutter are frequent complications
of cardiac surgery. In a prospective study (7) of 1,247 con-
secutive patients, 24% developed a postoperative atrial
tachyarrhythmia. Although prophylactic propranolol re-
duces the incidence of postoperative atrial tachyarrhythmias
to between 5 and 20%, these arrhythmias remain a problem
(6,12,13). Because acute atrial fibrillation and flutter fre-
quently terminate spontaneously within 24 hours, investi-
gations of the effects of antiarrhythmic drugs on conversion
of atrial tachyarrhythmias after cardiac surgery should be
placebo controlled. However, few placebo-controlled stud-
ies of antiarrhythmic drugs for postsurgical atrial fibrillation
have been performed (9,14).
The present data document for the first time that intra-
venous propafenone is beneficial and safe for the acute man-
agement of atrial fibrillation. Propafenone significantly slowed
the ventricular rate in atrial fibrillation or flutter and resulted
in prompt conversion to sinus rhythm in 43% of patients.
Previous studies on antiarrhythmic agents. There are
two placebo-controlled studies of intravenous verapamil for
atrial fibrillation occurring after cardiac surgery. Plumb et
al. (9) reported that low dose intravenous verapamil (0.075
mg/kg) decreased ventricular response to atrial fibrillation
from 150 ± 22 to 102 ± 14 beats/min and high dose
verapamil (0.15 mg/kg) decreased the response from 139
± ~4 to 97 ± 13 beats/min. Hwang et al. (14) reported a
similar decrease in ventricular response using the same dose
of verapamil. Verapamil was not effective for conversion
to sinus rhythm in either study.
Gray et al. (10) evaluated esmolol, a new ultrashort-
acting beta-blocker, in 11 patients with atrial fibrillation or
flutter occurring after open heart surgery in a nonrandomized
noncontrolled study. Esmolol caused a 30 ± II % decrease
in ventricular response. Although 5 of the II patients had
conversion to sinus rhythm during the 24 hour esmolol in-
fusion, no placebo group was available for comparison.
Gavaghan et al. (7) reported a large nonrandomized trial
of disopyramide and digoxin for control of atrial fibrillation
and flutter after cardiac surgery. Sixty percent of patients
had conversion to sinus rhythm during the 14 hour study
period. There was, however, a high incidence of side effects
(19%). Four patients with atrial flutter developed 1:I AV
node conduction in spite of prior digitalization, and one
patient developed ventricular tachycardia.
In a randomized trial (15) of sotalol versus disopyramide
and digoxin for atrial tachyarrhythmia after cardiac surgery,
there was no difference in the overall rate of arrhythmia
conversion between sotalol and digoxin/disopyramide, but
conversion occurred significantly earlier with sotalol. Sev-
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Figure 1. The effects of propafenone (n = 14) and placebo (n
= 10) on ventricular response to atrial fibrillation or flutter. Each
line representsone patient before and after receiving propafenone
or placebo. The dot and bars in the margins represent mean ±
standard deviation.
Effect on ventricular response. The effect of propa-
fenone on the ventricular response to atrial fibrillation or
flutter is shown in Figure 1. Ventricular rate recorded 5
minutes after the end of the drug infusion was used for this
analysis because this was the time of maximal slowing of
ventricular rate and because in all patients with conversion
to sinus rhythm the conversion occurred between 5 and 10
minutes after the infusion, After propafenone, the ventric-
ular response to atrial fibrillation or flutter decreased from
141.6 ± 15.2 to 116.0 ± 15.5 beats/min (p < 0.001).
After placebo, it decreased from 142 ± 17 to 140 ± 19
beats/min (p = NS).
Two patients in this study had atrial flutter, and neither
had conversion to sinus rhythm. Propafenone decreased the
ventricular response by 35 beats/min in one patient and
increased it by 7 beats/min in the other.
. Blood pressure. There was a small but statistically sig-
nificant (p < 0.01) reduction in systolic arterial blood pres-
sure of 9 ± 9 mm Hg during propafenone infusion that
caused no symptoms and did not require treatment. No other
side effects were observed.
Plasma concentrations. The mean propafenone plasma
concentration in all patients, obtained 1 to 5 minutes after
drug infusion, was 3.46 ± 2.17 mg/liter. There was no
significant difference between the mean propafenone plasma
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enteen of 20 patients receiving intravenous sotalol devel-
oped hypotension (systolic blood pressure decrease of 2::20
mm Hg or to <90 mm Hg).
Because of important differences in design between this
and other studies, it is not possible to compare propafenone
with most other drugs for conversion of postoperative atrial
fibrillation. Only verapamil has been evaluated by placebo-
controlled trial for postoperative atrial tachyarrhythmias,
and it was not effective for conversion to sinus rhythm.
Plasma concentrations of propafenone. These did not
differ significantly between patients with and without con-
versionto sinus rhythm. It is knownthat propafenone plasma
concentrations decrease very rapidly immediately after a
bolus infusion as a result of distribution of drug out of the
central compartment (16). Therefore, propafenone concen-
trations measured in our study may not reflect the plasma
concentration at the exact time of conversion.
Role of digoxin. Six patients in our study had received
digoxin before receiving propafenone. Although no inter-
action betweenpropafenone and digoxin has been reported,
it is possible that some of the effects attributed to propa-
fenone in this study werecaused by an effect of propafenone
on digoxin plasmaconcentrations. However, this is unlikely
becausepropafenonehad similareffects in patientswho had
and had not received digoxin.
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